Published in Clin Liver Dis on August 01, 2005
S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C | NCT00475176
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Canadian consensus on medically acceptable wait times for digestive health care. Can J Gastroenterol (2006) 4.34
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med (2011) 3.80
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol (2014) 2.85
Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology (2013) 2.62
Global control of hepatitis C: where challenge meets opportunity. Nat Med (2013) 2.22
Lack of response to exogenous interferon-alpha in the liver of chimpanzees chronically infected with hepatitis C virus. Hepatology (2007) 1.84
Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci (2007) 1.83
New antiviral therapies for chronic hepatitis C. Hepatol Int (2010) 1.71
HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep (2011) 1.65
The history of the "natural history" of hepatitis C (1968-2009). Liver Int (2009) 1.63
Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol (2014) 1.59
The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. Can J Gastroenterol (2008) 1.46
Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J Clin Immunol (2011) 1.34
Intragenotypic JFH1 based recombinant hepatitis C virus produces high levels of infectious particles but causes increased cell death. Virology (2008) 1.32
Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. Hepatology (2010) 1.28
Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res (2014) 1.17
Transcriptome sequencing, microarray, and proteomic analyses reveal cellular and metabolic impact of hepatitis C virus infection in vitro. Hepatology (2010) 1.17
Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women. J Clin Virol (2008) 1.15
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15
Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift. Saudi J Gastroenterol (2016) 1.11
In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother (2007) 1.09
Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B. Hepat Mon (2011) 1.06
Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors. Antimicrob Agents Chemother (2008) 1.05
Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother (2009) 1.03
Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology (2011) 1.02
The costs and impacts of testing for hepatitis C virus antibody in public STD clinics. Public Health Rep (2007) 1.01
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2014) 0.99
Effects of a hepatitis C virus educational intervention or a motivational intervention on alcohol use, injection drug use, and sexual risk behaviors among injection drug users. Am J Public Health (2009) 0.96
Viral hepatitis a to e in South mediterranean countries. Mediterr J Hematol Infect Dis (2010) 0.95
Hepatitis C: a clinical review. Oral Dis (2008) 0.94
Treatment of hepatitis C virus infection in the future. Clin Transl Med (2013) 0.93
Prospective follow-up of patients with acute hepatitis C virus infection in Brazil. Clin Infect Dis (2010) 0.92
The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study. Hepat Mon (2014) 0.90
Laser captured hepatocytes show association of butyrylcholinesterase gene loss and fibrosis progression in hepatitis C-infected drug users. Hepatology (2012) 0.89
Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis. PLoS One (2014) 0.89
The marmoset model of GB virus B infections: adaptation to host phenotypic variation. J Virol (2009) 0.89
Unhealthy alcohol use, HIV infection and risk of liver fibrosis in drug users with hepatitis C. PLoS One (2012) 0.88
A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations. BMC Public Health (2011) 0.87
All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Dig Dis Sci (2014) 0.86
Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review. World J Hepatol (2013) 0.85
Genetic variation in the interleukin-28B gene is associated with spontaneous clearance and progression of hepatitis C virus in Moroccan patients. PLoS One (2013) 0.85
A public health approach to hepatitis C control in low- and middle-income countries. PLoS Med (2015) 0.85
Association between serum vitamin D and severity of liver fibrosis in chronic hepatitis C patients: a systematic meta-analysis. J Zhejiang Univ Sci B (2014) 0.85
Computational reconstruction of Bole1a, a representative synthetic hepatitis C virus subtype 1a genome. J Virol (2012) 0.85
Pharmacogenomics of hepatitis C infections: personalizing therapy. Genome Med (2012) 0.84
Hepatitis C virus infection in the human immunodeficiency virus infected patient. World J Gastroenterol (2014) 0.84
Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study. BMJ Open (2014) 0.84
Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology (2016) 0.84
Rs12979860 and rs8099917 single nucleotide polymorphisms of interleukin-28B gene: simultaneous genotyping in caucasian patients infected with hepatitis C virus. J Prev Med Hyg (2013) 0.83
HAVCR1 gene haplotypes and infection by different viral hepatitis C virus genotypes. Clin Vaccine Immunol (2011) 0.83
The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis C. Hepat Mon (2011) 0.83
Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes. World J Gastroenterol (2015) 0.82
Never injected, but hepatitis C virus-infected: a study among self-declared never-injecting drug users from the Amsterdam Cohort Studies. J Viral Hepat (2009) 0.82
Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis. Exp Ther Med (2011) 0.81
Chronic hepatitis C virus infection and increases in viral load in a prospective cohort of young, HIV-uninfected injection drug users. Drug Alcohol Depend (2011) 0.80
Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil. BMC Infect Dis (2011) 0.80
GB virus C infection among young, HIV-negative injection drug users with and without hepatitis C virus infection. J Viral Hepat (2011) 0.80
Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia. J Med Virol (2012) 0.80
Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmission. BMC Res Notes (2015) 0.80
Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol (2017) 0.79
Inadequate awareness of hepatitis C among nonspecialist physicians in China. Adv Med Educ Pract (2011) 0.79
Lack of adaptation of chimeric GB virus B/hepatitis C virus in the marmoset model: possible effects of bottleneck. J Virol (2009) 0.79
Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin. Korean J Hepatol (2011) 0.79
Antiviral activity and host gene induction by tamarin and marmoset interferon-alpha and interferon-gamma in the GBV-B primary hepatocyte culture model. Virology (2009) 0.79
Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial. BMJ Open (2011) 0.79
Detection and significance of cytotoxic cell subsets in biopsies of HCV-infected human livers. Arch Immunol Ther Exp (Warsz) (2014) 0.78
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol (2012) 0.78
APRI as a predictor of early viral response in chronic hepatitis C patients. World J Gastroenterol (2009) 0.77
Evaluation of IL-28B polymorphisms and serum IP-10 in hepatitis C infected chimpanzees. PLoS One (2012) 0.77
Influence of human T-lymphotropic virus type 1 coinfection on the development of hepatocellular carcinoma in patients with hepatitis C virus infection. J Gastroenterol (2014) 0.77
Treatment of patients with HCV related cirrhosis: many rewards with very few risks. Hepat Mon (2012) 0.77
Human Interferon Regulatory Factor 2 Gene Expression is Induced in Chronic Hepatitis C Virus Infection-A Possible Mode of Viral Persistence. J Clin Exp Hepatol (2012) 0.77
Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein. Antimicrob Agents Chemother (2015) 0.77
Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C. J Viral Hepat (2011) 0.76
Era of direct acting antivirals in chronic hepatitis C: Who will benefit? World J Hepatol (2015) 0.76
Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes. Antimicrob Agents Chemother (2014) 0.76
Oxidative Stress Attenuates Lipid Synthesis and Increases Mitochondrial Fatty Acid Oxidation in Hepatoma Cells Infected with Hepatitis C Virus. J Biol Chem (2015) 0.76
Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients. World J Gastroenterol (2014) 0.75
Direct-acting antiviral agents in patients with hepatitis C cirrhosis. Gastroenterol Hepatol (N Y) (2012) 0.75
Novel biosensor-based microarray assay for detecting rs8099917 and rs12979860 genotypes. World J Gastroenterol (2012) 0.75
Influence of cytokine and cytokine receptor gene polymorphisms on the degree of liver damage in patients with chronic hepatitis C. Meta Gene (2016) 0.75
HCV genome-wide genetic analyses in context of disease progression and hepatocellular carcinoma. PLoS One (2014) 0.75
Clinical significance of perihepatic lymphadenopathy in patients with chronic hepatitis C infection. Dig Dis Sci (2011) 0.75
Statins and the risk of cirrhosis in hepatitis B or C patients: a systematic review and dose-response meta-analysis of observational studies. Oncotarget (2017) 0.75
Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway. BMC Infect Dis (2017) 0.75
Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era. Curr Epidemiol Rep (2017) 0.75
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med (2006) 8.37
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28
Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology (2006) 2.24
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
A framework for management of hepatitis C in prisons. Ann Intern Med (2006) 1.80
Hepatitis C and renal disease: an update. Am J Kidney Dis (2003) 1.65
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol (2002) 1.57
Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology (2008) 1.53
Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med (2004) 1.36
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol (2011) 1.20
Hepatotoxicity due to hydroxycut: a case series. Am J Gastroenterol (2010) 1.14
Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology (2004) 1.12
Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. Hepatology (2009) 1.12
Low-positive anti-hepatitis C virus enzyme immunoassay results: an important predictor of low likelihood of hepatitis C infection. Clin Chem (2003) 1.04
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology (2011) 0.98
Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. Metabolism (2003) 0.94
Complementary and alternative medicine (CAM) for the treatment of chronic hepatitis B and C: a review. Antivir Ther (2007) 0.93
Causality assessment for suspected DILI during clinical phases of drug development. Drug Saf (2014) 0.91
Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology (2011) 0.85
Sustained virologic response: is this equivalent to cure of chronic hepatitis C? Hepatology (2013) 0.84
Are herbals as safe as their advocates believe? J Hepatol (2008) 0.82
Liver injury induced by herbal complementary and alternative medicine. Clin Liver Dis (2013) 0.79
Viral load as a predictor of progression of chronic hepatitis C? Hepatology (2005) 0.79
Is cirrhosis an inevitable consequence of chronic hepatitis C virus infection? Clin Gastroenterol Hepatol (2005) 0.78
More severe parenchymal injury in chronic hepatitis C acquired by recent injection drug use. J Clin Gastroenterol (2005) 0.76
Hepatitis C infection and injection drug use: the role of hepatologists in evolving treatment efforts. Hepatology (2004) 0.76
Efforts to define the natural history of chronic hepatitis C continue. Clin Gastroenterol Hepatol (2006) 0.75